Literature DB >> 15122810

Early inhibition of nitric oxide production increases HSV-1 intranasal infection.

Gisela Gamba1, Hernan Cavalieri, Maria C Courreges, Ernesto J Massouh, Fabian Benencia.   

Abstract

Here, we studied the role of nitric oxide (NO) production during the first steps of the respiratory infection of BALB/c mice with herpes simplex virus type 1 (HSV-1), strain F. Nitric oxide synthase II (NOS-II) mRNA and protein were detected by reverse transcription (RT)-PCR and dot blot, respectively in samples of lungs and turbinates early post-infection (p.i.). Immunohistochemical analysis revealed pulmonar macrophages and PMN expressing NOS-II in the lungs of infected animals. Animals intranasally treated with aminoguanidine (AG), a NOS inhibitor, during the first steps of infection, showed a dose-dependent increase in pneumonitis compared to controls. Viral titres in turbinates, lungs, and brains were higher in AG treated mice. Finally, histopathology studies revealed a stronger inflammation in eyes, and lungs of these animals. Taken together, these results suggest a role of NO in controlling primary HSV intranasal infection. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122810     DOI: 10.1002/jmv.20093

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Herpes Simplex Virus 1 Suppresses the Function of Lung Dendritic Cells via Caveolin-1.

Authors:  Bing Wu; Shuang Geng; Yanmin Bi; Hu Liu; Yanxin Hu; Xinqiang Li; Yizhi Zhang; Xiaoyu Zhou; Guoxing Zheng; Bin He; Bin Wang
Journal:  Clin Vaccine Immunol       Date:  2015-05-27

Review 2.  Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise.

Authors:  Palak P Oza; Khosrow Kashfi
Journal:  Nitric Oxide       Date:  2022-08-24       Impact factor: 4.898

3.  Microglia are the major cellular source of inducible nitric oxide synthase during experimental herpes encephalitis.

Authors:  Cristina P Marques; Maxim C-J Cheeran; Joseph M Palmquist; Shuxian Hu; James R Lokensgard
Journal:  J Neurovirol       Date:  2008-05       Impact factor: 2.643

Review 4.  Herpes keratitis.

Authors:  A M Rowe; A J St Leger; S Jeon; D K Dhaliwal; J E Knickelbein; R L Hendricks
Journal:  Prog Retin Eye Res       Date:  2012-08-27       Impact factor: 21.198

5.  Guanidine modifications enhance the anti-herpes simplex virus activity of (E,E)-4,6-bis(styryl)-pyrimidine derivatives in vitro and in vivo.

Authors:  Wei Wang; Cuijing Xu; Jianqiang Zhang; Jinpeng Wang; Rilei Yu; Dongping Wang; Ruijuan Yin; Wenmiao Li; Tao Jiang
Journal:  Br J Pharmacol       Date:  2020-01-23       Impact factor: 8.739

Review 6.  Macrophages and cytokines in the early defence against herpes simplex virus.

Authors:  Svend Ellermann-Eriksen
Journal:  Virol J       Date:  2005-08-03       Impact factor: 4.099

Review 7.  The role of myeloid cell activation and arginine metabolism in the pathogenesis of virus-induced diseases.

Authors:  Kristina S Burrack; Thomas E Morrison
Journal:  Front Immunol       Date:  2014-09-08       Impact factor: 7.561

8.  Dendritic cells, macrophages, NK and CD8+ T lymphocytes play pivotal roles in controlling HSV-1 in the trigeminal ganglia by producing IL1-beta, iNOS and granzyme B.

Authors:  Natália Lucinda; Maria Marta Figueiredo; Natália Lima Pessoa; Beatriz Senra Álvares da Silva Santos; Graciela Kunrath Lima; Arthur Molinari Freitas; Alexandre Magalhães Vieira Machado; Erna Geessien Kroon; Lis Ribeiro do Valle Antonelli; Marco Antônio Campos
Journal:  Virol J       Date:  2017-02-21       Impact factor: 4.099

9.  N-acetylpenicillamine inhibits the replication of porcine reproductive and respiratory syndrome virus in vitro.

Authors:  Yunbo Jiang; Liurong Fang; Rui Luo; Shaobo Xiao; Huanchun Chen
Journal:  Vet Res Commun       Date:  2010-07-31       Impact factor: 2.459

10.  The role of nitric oxide in mycobacterial infections.

Authors:  Chul-Su Yang; Jae-Min Yuk; Eun-Kyeong Jo
Journal:  Immune Netw       Date:  2009-04-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.